Ur Metser

Lymphoscintigraphic sentinel node identification in patients with breast cancer: the role of SPECT-CT.

PurposeLymph node status is a major factor in determining the stage, appropriate therapy and outcome in patients with breast cancer. It is therefore of clinical importance to accurately identify all sentinel nodes (SNs) for each individual tumour before surgery. The purpose of this study was to assess the role of SPECT-CT lymphoscintigraphy in SN identification in patients with breast cancer.MethodsLymphoscintigraphy comprising planar and SPECT-CT acquisition was performed in 157 consecutive patients with breast cancer (mean age 54.7±10.6, range 27–81 years) with a palpable mass (n=100), with a non-palpable mass (n=52) or post lumpectomy (n=5). Planar and SPECT-CT images were interpreted separately and the two imaging techniques were compared with respect to their ability to identify hot nodes.ResultsPlanar imaging alone was negative for identification of hot nodes in 15% of the patients. SPECT-CT alone was negative in 10% and both techniques were negative in 9% of the patients. Forty-six of the total of 361 (13%) hot nodes identified by lymphoscintigraphy were detected only on SPECT-CT, including 21 nodes obscured by the scattered radiation from the injection site, nine adjacent nodes misinterpreted on planar images as a single node and 16 nodes which were missed on planar images and detected on SPECT data. SPECT-CT detected additional sites of drainage unexpected on planar images, including axillary (n=23 patients), internal mammary (n=5 patients), interpectoral (n=3 patients) and intramammary (n=2 patients) lymph node sites. Fourteen of the 329 (4%) hot lesions seen on planar images were false positive non-nodal sites of uptake that were accurately assessed by SPECT-CT and further validated by surgery. In a single patient, SPECT-CT was negative while planar images identified the SN.ConclusionSPECT-CT may improve the preoperative localisation of draining nodes in patients with breast cancer. It may detect hot nodes missed by planar imaging, exclude non-nodal false positive sites of uptake and accurately localise axillary and extra-axillary nodes.

Lymphoscintigraphy for sentinel node mapping using a hybrid single photon emission CT (SPECT)/CT system in oral cavity squamous cell carcinoma.

We assessed the added clinical value of fused single photon emission computed tomography (SPECT) and low‐dose CT images compared with planar images for sentinel node (SN) mapping in patients with oral cavity squamous cell carcinoma (SCC).

The presentation of malignant tumours and pre-malignant lesions incidentally found on PET-CT

PurposeThe purpose of the study was to determine the general and organ-specific presentation of incidental primary tumours on PET-CT.MethodsPET-CT reports of 2,360 consecutive patients were reviewed and revealed 156 lesions suspicious for a new unexpected malignancy, in 151 patients. One hundred and twenty of these lesions, in 115 patients, were further assessed, by biopsy (n=84 patients) or by clinical and imaging follow-up (n=31 patients) for a mean of 17±4 months (range 12–25 months).ResultsForty-four unexpected malignancies were found in 41 of the study patients (1.7%). Twenty-seven of the 44 incidental tumours were identified on the basis of their location, which was uncommon for metastasis of the known malignancy. Eight were detected as a result of either the difference in FDG avidity of the known malignancy and the incidental lesion or the presence of an incidental non-FDG-avid mass on the CT part of the study. Four tumours were synchronous carcinomas in patients with known colorectal malignancy, three were identified by virtue of the discordant response to treatment compared with the known primary tumour and two were detected as new sites of disease after a prolonged disease-free period. There was organ variability in the positive predictive values (PPV) of PET-CT findings for incidental primary malignancy or pre-malignant lesions: 62% for colonic lesions, 54% for lung lesions and 24% for thyroid lesions.ConclusionIncidental primary tumours may be identified on PET-CT based on their location, FDG avidity, response to therapy and time of appearance. The PET and CT parts of the study appear to complement each other and assist in identification of these incidental tumours.

PET‐CT imaging of combined brachial and lumbosacral neurolymphomatosis

Abstract:u2002 Neurolymphomatosis is a rare manifestation of progressive non‐Hodgkins lymphoma. A 44‐yr‐old man with diffuse large B‐cell lymphoma presented with unilateral progressive peripheral sensorimotor neuropathy after the 7th cycle of R‐CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) therapy. No pathology in the nervous system was evident by computerized tomography (CT), magnetic resonance imaging (MRI) of the head, spinal axis and plexuses and by repeated analysis of cerebrospinal fluid. However, the hybrid modality of positron emission tomography (PET) of fluorinated deoxyglucose (FDG) combined with CT scan (PET‐CT) showed unilateral involvement of both the brachial and lumbosacral nervous plexuses. A complete recovery of neurological manifestations and normalization of PET‐CT followed intensive chemotherapy with autologous stem cell transplantation. The diagnosis and localization of neurolymphomatosis may be supported by PET‐CT imaging.

Assessment of neurolymphomatosis by brachial plexus biopsy and PET/CT. Report of a case.

Objective: To report a biopsy-proven neurolymphomatosis in a young woman with previous non-Hodgkin’s lymphoma (NHL) of uterine cervix.Patient: The patient presented with a painful brachial plexopathy and developed multiple cranial and spinal nerve palsies.Methods and results: The diagnosis was achieved by an open brachial plexus biopsy. A PET/CT study was used to assess the full extent of the disease and showed involvement of additional cranial nerves and spinal nerve roots. A complete although short lasting clinical and radiological response was achieved by means of systemic high dose methotrexate treatment combined with rituximab and intra-CSF injections of cytarabine.

Early-mid treatment C-reactive protein level is a prognostic factor in aggressive non-Hodgkin's lymphoma

Background:u2002 In the light of an emerging role for early‐mid treatment 18u2003F‐deoxyfluoroglucose positron emission tomography (FDG‐PET) as an important prognostic indicator in aggressive non‐Hodgkin’s lymphoma (NHL) , we attempted to determine whether a simple parameter, such as the early‐mid treatment CRP (C‐reactive protein) level, could also be utilized as a significant prognostic factor in aggressive NHL.